Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter

C.-J. Wu[1,2], H.-C. Lee[2], Y.-L. Yang[3,4], C.-M. Chang[2], H.-T. Chen[1,3], C.-C. Lin[1], N.-Y. Lee[2], W.-L. Chu[1], L.-Y. Hsieh[1], Y.-L. Wang[2], T.-L. Lauderale[1], F.-C. Tseng[1], N.-Y. Ko[5], W.-C. Ko[2] and H.-J. Lo[1,6]

1) National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan, 2) Division of Infectious Diseases, Department of Internal Medicine and Centre for Infection Control, National Cheng-Kung University Hospital and Medical College, Tainan, Taiwan, 3) Institute of Molecular Medicine and Bioengineering, 4) Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan, 5) Department of Nursing, College of Medicine, National Cheng Kung University, Tainan, Taiwan and 6) School of Dentistry, China of Medical University, Taichung, Taiwan

Abstract

To understand the status of oropharyngeal yeast colonization in human immunodeficiency virus (HIV) -infected outpatients in the era of highly active antiretroviral therapy (HAART), we conducted a prospective, cross-sectional study from October 2009 to January 2010 at a medical centre in southern Taiwan. Fungal cultures of the oropharyngeal swabs were performed on 327 enrolled patients. At enrolment, 258 (79%) patients had been receiving HAART, and 42 (12.8%), 73 (22.3%) and 212 (64.8%) patients had CD4 cell counts $\leq$200, 201–350, and >350 cells/mm^3, respectively. Oral yeast colonization was detected in 193 (59%) patients, among whom 157 (81.3%), 25 (13.0%), and 11 (5.7%) were colonized by a single, two and more than two species, respectively. Multivariate analysis showed that receipt of efavirenz-containing regiments and CD4 cell counts >200 cells/mm^3 were associated with lower risks of oral yeast colonization, while intravenous drug users were at a higher risk. Among the 241 isolates recovered, Candida albicans accounted for 69.7%, followed by C. dubliniensis (9.5%), C. glabrata (8.3%), C. tropicalis (3.3%), C. intermedia (2.1%), C. parapsilosis (1.7%), and 11 other species (5.4%). Overall, 230 (95.4%), 236 (97.9%) and 240 (99.6%) isolates were susceptible to fluconazole, voriconazole and amphotericin B, respectively. In conclusion, colonization by C. dubliniensis has emerged in recent years. In addition to a CD4 cell count $\leq$200 cells/mm^3, which is a known risk factor for oropharyngeal yeast colonization in HIV-infected patients that was identified in our previous studies, two risk factors, non-receipt of efavirenz-based combinations and intravenous drug use, were first identified in the present study. Fluconazole remained effective in vitro against the yeasts colonizing the oropharynx in this population.

Corresponding authors: W.-C. Ko, Division of Infectious Diseases, Department of Internal Medicine, National Cheng Kung University Hospital, No. 138, Sheng Li Road, 704 Tainan, Taiwan
E-mail: winston@mail.ncku.edu.tw
and
H.-J. Lo, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County, Taiwan
E-mail: hjlo@nhri.org.tw

Introduction

Oropharyngeal colonization by Candida species in human immunodeficiency virus (HIV) -infected patients [1–4] may evolve to oro-oesophageal candidiasis during progressive immunodeficiency [5], which can subsequently hamper the nutritional intake of patients and increase the medical cost of patient management. In HIV-infected patients, Candida

albicans is the main species of colonization [3,6]. However, colonization by *C. dubliniensis* has increased in recent years [3,7,8]. Oral candidiasis usually responds to effective antifungal agents, but the antifungal susceptibility profile varies with *Candida* species and previous use of antifungal agents [9].

In Taiwan, the overall prevalence of HIV infections increased from 0.16‰ in 2001 to 0.89‰ in 2010 [10]. The government has been providing free highly active antiretroviral therapy (HAART) to HIV-infected patients in Taiwan since 1997. Consequently, the number of patients receiving HAART has increased in the recent decade. Although the risk factors and species distribution of oropharyngeal yeast colonization in HIV-infected patients had been discussed in our previous studies conducted in 1999–2002 and 2005 [1,6], the effect of different antiretroviral agents on colonization was not addressed. Moreover, there was a dramatic increase in the population of HIV-infected intravenous drug users (IDUs) between 2004 and 2006 in Taiwan [11]. Facing a changing epidemiology, we conducted another survey between 2009 and 2010 to investigate the risk factors and species distribution of oropharyngeal yeast colonization in HIV-infected patients and the antifungal susceptibility of isolates recovered from the survey, with the hope of providing useful information to assist the population.

Materials and Methods

Study population and data collection

This prospective cross-sectional study was conducted from October 2009 to January 2010. The study was approved by the Human Experiment and Ethics Committee of National Chen-Kung University Hospital, a medical centre in southern Taiwan. HIV-infected patients at the outpatient infectious diseases clinic were enrolled after informed consents had been obtained. A standardized data collection form was used to retrieve demographic characteristics (age, gender and types of HIV transmission), known period of HIV infection, the underlying medical conditions, and information within the 6 months prior to enrolment, including the presence of oral thrush, the latest CD4 cell counts and HIV viral loads, history of hospitalization and residence in jails or rehabilitation centres, and recent receiving of antibacterial/antifungal treatments for ≥ 1 day, and antiretroviral agents for ≥ 2 weeks within 3 months of enrolment.

Sample collection and fungal cultures

Oropharyngeal swabs were obtained using a dry sponge swab (EZ Culturette; Becton Dickinson, Sparks, MD). All swabs were maintained at room temperature and transported to the central laboratory at the National Health Research Institutes within 24 h. The swabs were then streaked onto Chromagar *Candida* agar medium (CHROMagar, Paris, France). All plates were incubated at 30°C. Three, if present, colonies from each plate were selected for further analyses. Additional colonies were selected from the plates when there was more than one morphotype present. All isolates were subjected to the VITEK Yeast Biochemical Card (bioMérieux; Marcy l'Etoile, France) for species identification. When the Yeast Biochemical Card identification probability was less than 90% or when uncommon species were reported, the sequences of the internal transcribed spacer (ITS) region and the D1/D2 region of ribosomal DNA were used for species identification. The ITS regions were amplified using the primers ITS1, 5′-TCCGTAGGTGAACCT GCGG-3′ and ITS4 5′-TCCTCCGCTTATTGATATGC-3′, and the D1/D2 regions were amplified using the primers NL1 5′-GCATATCAATAAGCGGAGGAAAAG-3′ and NL4 5′-GGTCCGTGTTTCAAGACGG-3′ [12,13].

Antifungal susceptibility tests

The MICs of antifungal drugs were determined according to the guidelines of M27-A3 recommended by the Clinical and Laboratory Standards Institute [14]. The RPMI-1640 medium (31800–022, Gibco BRL, Carlsbad, CA) was used for the dilution and growth of the yeast culture. Strains from American Type Culture Collection (ATCC, Manassass, VA), including *C. albicans* (ATCC 90028), *C. krusei* (ATCC 6258) and *C. parapsilosis* (ATCC 22019), were used as the standard controls. Growth of each isolate was measured by the Biotrak II plate spectrophotometric reader (Amersham Biosciences, Biochrom Ltd., Cambridge, UK) after incubation at 35°C for 48 h.

The MICs for amphotericin B and azoles were defined as the lowest concentrations capable of preventing any discernible growth and of reducing the turbidity of cells by >50%, respectively. For amphotericin B, MICs of ≥2 μg/mL were considered resistant and ≤1 μg/mL susceptible. For fluconazole, MICs of ≥64 μg/mL were considered resistant and ≤8 μg/mL susceptible. The isolates with MICs in the range of 16–32 μg/mL were referred to as susceptible-dose-dependent. For voriconazole, MICs of ≥4 μg/mL were considered resistant and ≤1 μg/mL susceptible [14]. Generally, only one isolate of each patient was analysed. Nevertheless, when a patient was colonized by more than one species, one isolate of each species was included.

Statistical methods

The results were analysed with SPSS software for Windows, version 12.0. Variables collected in the data collection form

were tested for association with yeast colonization and infection. The chi-square test was applied for categorical variables, and the Student's *t*-test for continuous variables. Logistic regression was applied to assess the independent effects of factors found to be significant in the univariate analysis. A p value <0.05 was considered significant.

Results

Patients

During the study period, a total of 327 patients were enrolled. Their demographic data are shown in Table 1. They were predominantly men (299, 91.4%) and 36 (11%) patients were IDUs. Overall, 42 (12.8%), 73 (22.3%) and 212 (64.8%) patients had a CD4 cell count ≤200, 201–350 and >350 cells/mm^3, respectively. At enrolment, 258 (79%) patients were receiving HARRT.

Status and risk factors for yeast colonization

Of the 327 patients, 193 (59%) were colonized by yeasts, among whom 157 (81.3%), 25 (13.0%) and 11 (5.7%) were by single, two and more than two species, respectively. A higher proportion of patients with low CD4 cell counts were colonized by yeasts than those with higher counts (81% in ≤200/mm^3 versus 56% in >200/mm^3, p 0.002). By univariate analysis, patients who were IDUs, patients who had been exposed to antibacterial agents, and patients who received mycostatin oral suspension in the previous 6 months were at risk for colonization, whereas a CD4 cell count >200 cells/mm^3 and being in receipt of lamivudine or lamivudine/zidovudine, or efavirenz protected patients from colonization. Use of protease inhibitors (atazanavir or lopinavir/ritonavir) had no significant effect on colonization (p 0.26). By multivariate analysis, receipt of efavirenz and a CD4 count >200 cells/mm^3 protected patients from colonization, whereas IDUs were at risk for colonization (Table 1). Furthermore, the protective effect of efavirenz-based antiretroviral therapy on

TABLE 1. Characteristics of 327 human immunodeficiency virus (HIV) -infected patients enrolled for oropharyngeal fungal cultures and predictors of positive culture for yeasts

Characteristic	All (*n* = 327)	Yeast culture Positive (*n* = 193)	Negative (*n* = 134)	Univariate p value	Multivariate p value, OR (95% CI)
Age, years (mean ± SD)	38.7 ± 12.8	39.6 ± 12.7	37.5 ± 13.0	0.146	
CD4, cells/mm^3 (mean ± SD)	477.8 ± 283.7	455.3 ± 246.5	524.7 ± 325.3	0.013	
HIV viral load, log (copies/mm^3) (mean ± SD)	2.05 ± 1.27 (*n* = 324)	2.15 ± 1.32 (*n* = 190)	1.91 ± 1.19	0.092	
Known period of HIV infection, years (mean ± SD)	5.21 ± 3.72	5.32 ± 3.81	5.05 ± 3.61	0.53	
No. of subjects with indicated transmission type (%)					
Men having sex with men or bisexual	179 (54.7%)	103 (53.4%)	76 (56.7%)	0.574	
Heterosexual	101 (30.9%)	57 (29.5%)	44 (32.8%)	0.545	
Intravenous drug user	36 (11%)	28 (14.5%)	8 (6%)	0.019*	0.031 2.53 (1.09–5.86)
Males, no. (%)	299 (91.4%)	175 (90.7%)	124 (92.5%)	0.689	
CD4 counts >200 cells/mm^3, no. (%)	285 (87.2%)	159 (82.4%)	126 (94%)	0.002*	0.002 0.27 (0.12–0.62)
Diabetes mellitus, no. (%)	11 (3.4%)	8 (4.1%)	3 (2.2%)	0.535	
Chronic kidney diseases, no. (%)	2 (0.6%)	2 (1%)	0 (0%)	0.515	
Hospitalization within 6 months, no. (%)	111 (33.9%)	60 (31.1%)	51 (38.1%)	0.194	
Residence in a jail or rehabilitation centre within 6 months, no. (%)	2 (0.6%)	1 (0.5%)	1 (0.7%)	1	
Medications					
Antiretroviral therapy within 3 months	258 (78.9%)	146 (75.6%)	112 (83.6%)	0.098	
lamivudine/zidovudine	134 (41.0%)	71 (36.8%)	63 (47.0%)	0.068	
l zidovudine or lamivudine/zidovudine	136 (41.6%)	72 (37.3%)	64 (47.8%)	0.068	
l lamivudine or lamivudine/zidovudine	239 (73.1%)	132 (68.4%)	107 (79.9%)	0.023*	
l stavudine	14 (4.3%)	10 (5.2%)	4 (3%)	0.413	
l abacavir	96 (29.4%)	53 (27.5%)	43 (32.1%)	0.389	
l didanosine	33 (10.1%)	22 (11.4%)	11 (8.2%)	0.36	
l efavirenz	101 (30.9%)	45 (23.3%)	56 (41.8%)	<0.001*	0.005 0.48 (0.29–0.80)
l nevirapine	18 (5.5%)	10 (5.2%)	8 (6%)	0.808	
l atazanavir	21 (6.4%)	15 (7.8%)	6 (4.5%)	0.26	
l lopinavir/ritonavir	117 (35.8%)	73 (37.8%)	44 (32.8%)	0.412	
l PI^a (atazanavir or lopinavir/ritonavir)	21 (6.4%)	15 (7.8%)	6 (4.5%)	0.26	
Antibacterials within 6 months	42 (12.0%)	33 (17.1%)	9 (6.7%)	0.007*	
Antifungals within 6 months					
l fluconazole	6 (1.8%)	6 (3.1%)	0 (0%)	0.085	
l amphotericin B	2 (0.6%)	1 (0.5%)	1 (0.7%)	1	
l mycostatin oral suspension	10 (3.1%)	10 (5.2%)	0 (0%)	0.006*	

*Variables entered in the multivariate analysis.
^{a}PI, protease inhibitor; OR, odds ratio; CI, confidence interval; SD, standard deviation.

TABLE 2. Species distribution and antimicrobial susceptibilities of yeasts recovered from the oropharynx of human immuno-deficiency virus-infected patients

Yeast	No. of isolates (%) with indicated minimum inhibitory concentrations (μg/mL)								Total no. of isolates (%)
	Fluconazole			Voriconazole			Amphotericin B		
	S, ≤8	SDD, 16–32	R, ≥64	S, ≤1	SDD, 2	R, ≥4	S, ≥1	R, ≥2	
Candida albicans	163	1	4 (2.4)	165	0	3 (1.8)	168	0	168 (69.7)
Candida dubliniensis	22	0	1 (4.3)	22	0	1 (4.5)	22	1 (4.3)	23 (9.5)
Candida glabrata	19	1	0	20	0	0	20	0	20 (8.3)
Candida tropicalis	7	0	1 (12.5)	7	0	1 (12.5)	8	0	8 (3.3)
Candida intermedia	5	0	0	5	0	0	5	0	5 (2.1)
Candida parapsilosis	4	0	0	4	0	0	4	0	4 (1.7)
Saccharomyces cerevisiae	3	0	0	3	0	0	3	0	3 (1.2)
Candida famata	1	0	0	1	0	0	1	0	1 (0.4)
Candida galeiformis	0	1	0	1	0	0	1	0	1 (0.4)
Candida guilliermondii	1	0	0	1	0	0	1	0	1 (0.4)
Candida inconspicua	0	1	0	1	0	0	1	0	1 (0.4)
Candida krusei	0	0	1 (100)	1	0	0	1	0	1 (0.4)
Candida lusitaniae	1	0	0	1	0	0	1	0	1 (0.4)
Candida rugosa	1	0	0	1	0	0	1	0	1 (0.4)
Cryptococcus neoformans	1	0	0	1	0	0	1	0	1 (0.4)
Kodamaea ohmeri	1	0	0	1	0	0	1	0	1 (0.4)
Metschnikowia spp.	1	0	0	1	0	0	1	0	1 (0.4)
Total	230 (95.4)	4 (1.7)	7 (2.9)	236 (97.9)	0 (0)	5 (2.1)	240 (99.6)	1 (0.4)	241 (100)

S, susceptible; SDD, susceptible-dose-dependent; R, resistant.

colonization remained significant even in a subgroup analysis of 258 patients receiving HAART. Receipt of efavirenz (OR, 0.474; 95% CI 0.28–0.804; p 0.006) and a CD4 count >200 cells/mm^3 (OR, 0.362; 95% CI 0.139–0.942; p 0.037) were two negative predictors for colonization based on multivariate analysis.

As for oral yeast infections, 11 of the 327 patients had experienced oral thrush in the 6 months before the study and five patients had oral thrush at the time of enrolment. Overall, 15 (4.7%) patients had recent or current oral thrush. Patients with a CD4 cell count ≤200 cells/mm^3 had a higher rate of recent or current oral thrush than those with a CD4 cell count >200 cells/mm^3 (28.6% versus 1%, p < 0.001), and multivariate analysis showed that a CD4 cell count ≤200 cells/mm^3 was the only independent factor associated with the development of oral thrush (OR, 12.8; 95% CI 1.08–150.4; p 0.043). Among the 193 patients with yeast colonization, a CD4 cell count ≤200 cells/mm^3 (OR, 9.37; 95% CI 1.48–59.2; p 0.017) and previous exposure to antibacterial agents (OR, 9.9; 95% CI 1.50–65.4; p 0.017) were the two variables associated with oral thrush based on multivariate analysis.

Species distribution and antifungal susceptibility of yeasts
Of the 241 yeast isolates characterized, 12 isolates needed to be speciated by DNA sequencing of the ribosomal DNA fragments. Seven isolates, including three *C. glabrata*, two *C. albicans*, one *C. guilliermondii* and one *C. membranifaciens*, were identified by sequencing the ITS fragments and four isolates, including one each of *C. glabrata*, *C. inconspicua*,

C. membranifaciens and *C. tropicalis*, were identified by sequencing the D1/D2 fragments. The remaining isolate, *Metschnikowia* spp., could not be identified to species level even using both ITS and D1/D2 sequence. The colonization species were *C. albicans* (168, 69.7%), *C. dubliniensis* (23, 9.5%), *C. glabrata* (20, 8.3%), *C. tropicalis* (8, 3.3%), *C. intermedia* (5, 2.1%), *C. parapsilosis* (4, 1.7%) and *Saccharomyces cerevisiae* (3, 1.2%), and others (10, 4.0%) (Table 2). Overall, *Candida* species accounted for 97.5% of these isolates. All 15 patients with previous or current oral thrush were colonized by *C. albicans* at enrolment, and two were simultaneously colonized by *C. tropicalis*, one by *C. dubliniensis* and one by *C. glabrata*.

Patients with *C. albicans* colonization were significantly younger than those with non-*C. albicans* yeasts (39.6 versus 43.6 years, p 0.037). Risk factors for *C. dubliniensis* colonization were not identified. Furthermore, patients colonized with multiple species were associated with a longer known period of HIV infection (4.6 versus 3.5 years, p 0.011) and prior exposure to penicillin derivatives (OR, 9.0; 95% CI 1.28–63.92; p 0.027).

Of the 241 isolates, 230 (95.4%), 236 (97.9%) and 240 (99.6%) isolates were susceptible to fluconazole, voriconazole and amphotericin B, respectively (Table 2). Seven (2.4%) and five (2.1%) isolates, mostly *C. albicans* (four and three isolates), were resistant to fluconazole and voriconazole, respectively. Eight *Candida* isolates, including six *C. albicans* isolates, one *C. dubliniensis* and one *C. glabrata*, were recovered from six patients who had received fluconazole for oral thrush. Of these eight isolates, only the *C. glabrata* isolate

had increased MICs of fluconazole (8 μg/mL) and voriconazole (0.25 μg/mL) whereas the other seven isolates remained susceptible to fluconazole (MIC $\leq$1 μg/mL) and voriconazole ($\leq$0.03 μg/mL), irrespective of previous fluconazole exposure.

Discussion

The demographic and microbiological characteristics of oropharyngeal yeast colonization in HIV-infected and non-HIV-infected populations in our previous reports [1,6,15] and the present study were compared. With the introduction of HAART, the mean CD4 cell counts gradually increased over time (from 208 cells/mm³ in 1999–2002 to 478 cells/mm³ in 2009–2010, respectively), which coincided with a reduced rate of patients with recent or current oral thrush (from 12.9% in 1999–2002 to 4.7% in 2009–2010). There were more HIV-infected IDUs enrolled in the present study. Previous studies have found the rate of oral *Candida* colonization among HIV-infected individuals to range from 44 to 82.8% [1–4]. In our earlier surveys, more than half of HIV-infected patients were colonized by yeasts [1,6] compared with only 15.2% of the healthy individuals in 2007 [15]. These findings suggested that HIV-infected patients are at risk for oropharyngeal yeast colonization, and this continues despite wide use of HAART. Among the isolates from HIV-infected patients, 87% in 1999–2002 [6] and 70% in the present study were *C. albicans*. Hence, the prevalence of non-albicans *Candida* species has indeed increased in the past decade.

Clinical information about the effects of different antiretroviral agents on the risk of oropharyngeal yeast colonization or infection is limited. In 2000, HIV protease inhibitors were the first to be associated with a lower rate of oropharyngeal *Candida* colonization and candidiasis [16]. The positive impact of protease inhibitors has been attributed to a better immunological function with their use, or with their antifungal activity resulting from the similar structure of *Candida*-secreted aspartic protease with the targeted protein, i.e. HIV aspartic protease [17]. However, such an effect of protease inhibitors was not found in the present study as well as in another recent study [2]. Instead we found that receipt of an efavirenz-containing regimen was significantly associated with a lower frequency of oropharyngeal yeast colonization both in all enrolled patients and in patients receiving HAART. This is the first study showing the potential effect of efavirenz on oropharyngeal yeast colonization. Despite the statistical significance of efavirenz on reduced colonization, further clinical investigations involving more patients to determine the impact of the drug on colonization and *in vitro* antifungal activity are warranted.

In our previous study conducted in 2005 [1], we found that all six IDUs were colonized by yeasts and had a CD4 count of >450 cells/mm³. This observation suggested that IDUs may be at risk for yeast colonization. In the present study, we were able to reach a statistically significant association between IDU and yeast colonization. An earlier report had a similar finding, showing a higher prevalence of *Candida* lesions and oral yeast colonization among the HIV-infected IDU group than the HIV-infected heterosexual and homosexual groups [18]. Furthermore, studies showed that IDUs, regardless of their HIV serostatus, were more likely than homosexual men to present with oral candidiasis [19–21]. Several factors of the lifestyle, access to health care, and the hygiene conditions of the oral cavity before HIV infection, influenced the development of oral lesions in HIV-infected populations [20]. Whether those same factors contribute to oropharyngeal yeast colonization needs to be examined.

Candida albicans was the major species, accounting for 70% of all yeast isolates colonizing the oropharynx of HIV-infected patients, a finding similar to previous studies in which *C. albicans* accounted for 60–83% of colonized isolates [3,22,23], although a decreased isolation rate was found compared with that (87%) of our earlier study during 1999–2002 [6]. Another shift of species distribution in our studies was noted in *C. dubliniensis*, which was not recovered during 1999–2002 [6] but was increasingly detected in 2005 (4.3%) [1] and in the present study (9.5%). Little is known about the risk factors for *C. dubliniensis* colonization in HIV-infected patients, except for a higher prevalence in individuals of European descent (9%) compared with individuals of African descent (1.5%) in South Africans [24]. Neither did our study identify the risk factors for *C. dubliniensis* colonization. The clinical implication of these findings remains to be elucidated.

In conclusion, compared with our previous studies, CD4 cell counts $\leq$200 cells/mm³ remained as a risk factor for oropharyngeal yeast colonization in HIV-infected patients, whereas non-receipt of efavirenz-based combinations and IDU were first identified as another two risk factors in the present study. The mechanism contributing to the effect of efavirenz on oropharyngeal yeast colonization needs further investigation. An increasing proportion of colonization by *C. dubliniensis* was also observed during the decade. Three tested antifungal agents, fluconazole, voriconazole and amphotericin B, remained effective against >95% of the colonized yeasts.

Acknowledgements

Author Contributions

C. J. Wu collected specimens and medical information from patients, analysed the data and drafted the manuscript. H. C. Lee, C. M. Chang, N. Y. Lee, Y. L. Wang, N. Y, Ko and W. C. Ko collected specimens and medical information from patients. H. T. Chen, C. C. Lin and W. L. Chu performed experiments for identification of isolates and drug susceptibilities. L. Y. Hsieh and F. C. Tseng analysed data. Y. L. Yang, W. C. Ko, T. L. Lauderdale and H. J. Lo designed the study and edited the manuscript. All authors made a significant contribution to this work.

Transparency Declaration

References

1. Yang YL, Hung CC, Wang AH *et al.* Oropharyngeal colonization of HIV-infected outpatients in Taiwan by yeast pathogens. *J Clin Microbiol* 2010; 48: 2609–2612.
2. Delgado AC, De Jesus Pedro R, Aoki FH *et al.* Clinical and microbiological assessment of patients with a long-term diagnosis of human immunodeficiency virus infection and *Candida* oral colonization. *Clin Microbiol Infect* 2009; 15: 364–371.
3. Erkose G, Erturan Z. Oral *Candida* colonization of human immunodeficiency virus infected subjects in Turkey and its relation with viral load and CD4$^+$ T-lymphocyte count. *Mycoses* 2007; 50: 485–490.
4. Patel M, Shackleton JT, Coogan MM. Effect of antifungal treatment on the prevalence of yeasts in HIV-infected subjects. *J Med Microbiol* 2006; 55: 1279–1284.
5. Vargas KG, Joly S. Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. *J Clin Microbiol* 2002; 40: 341–350.
6. Hung CC, Yang YL, Lauderdale TL *et al.* Colonization of human immunodeficiency virus-infected outpatients in Taiwan with *Candida* species. *J Clin Microbiol* 2005; 43: 1600–1603.
7. Binolfi A, Biasoli MS, Luque AG, Tosello ME, Magaro HM. High prevalence of oral colonization by *Candida dubliniensis* in HIV-positive patients in Argentina. *Med Mycol* 2005; 43: 431–437.
8. Sullivan D, Haynes K, Bille J *et al.* Widespread geographic distribution of oral *Candida dubliniensis* strains in human immunodeficiency virus-infected individuals. *J Clin Microbiol* 1997; 35: 960–964.
9. Masia Canuto M, Gutierrez Rodero F, Ortiz de la Tabla Ducasse V *et al.* Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant *Candida* strains in HIV-infected patients. *Eur J Clin Microbiol Infect Dis* 2000; 19: 593–601.
10. National notifiable disease surveillance system, 2001–2010. Taiwan: Centers for diseases control. [In Chinese] available at http://www.cdc.gov.tw [date accessed: March 28, 2011].
11. Liu JY, Lin HH, Liu YC *et al.* Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan. *Clin Infect Dis* 2008; 46: 1761–1768.
12. Leaw SN, Chang HC, Barton R, Bouchara JP, Chang TC. Identification of medically important *Candida* and non-*Candida* yeast species by an oligonucleotide array. *J Clin Microbiol* 2007; 45: 2220–2229.
13. Leaw SN, Chang HC, Sun HF, Barton R, Bouchara JP, Chang TC. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. *J Clin Microbiol* 2006; 44: 693–699.
14. Clinical and Laboratory Standards Institute. *Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard*, 3rd edn. CLSI document m27-a3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
15. Yang YL, Leaw SN, Wang AH, Chen HT, Cheng WT, Lo HJ. Characterization of yeasts colonizing in healthy individuals. *Med Mycol* 2011; 49: 103–106.
16. Arribas JR, Hernandez-Albujar S, Gonzalez-Garcia JJ *et al.* Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. *AIDS* 2000; 14: 979–985.
17. Hoegl L, Thoma-Greber E, Rocken M, Korting HC. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study. *Mycoses* 1998; 41: 321–325.
18. Ceballos Salobreña A, Gaitán Cepeda LA, Ruesga MT, Ceballos García L, Quindós G. Prevalence of oral lesions by *Candida* sp.: their varieties and serotypes in a population of patients with AIDS under a highly active antiretroviral therapy. *Revista Iberoamericana de Micología* 1998; 15: 141–145.
19. Phelan JA, Begg MD, Lamster IB *et al.* Oral candidiasis in HIV infection: predictive value and comparison of findings in injecting drug users and homosexual men. *J Oral Pathol Med* 1997; 26: 237–243.
20. Lamster IB, Begg MD, Mitchell-Lewis D *et al.* Oral manifestations of HIV infection in homosexual men and intravenous drug users. Study design and relationship of epidemiologic, clinical, and immunologic parameters to oral lesions. *Oral Surg Oral Med Oral Pathol* 1994; 78: 163–174.
21. Palenicek J, Nelson KE, Vlahov D, Galai N, Cohn S, Saah AJ. Comparison of clinical symptoms of human immunodeficiency virus disease between intravenous drug users and homosexual men. *Arch Intern Med* 1993; 153: 1806–1812.
22. Luque AG, Biasoli MS, Tosello ME, Binolfi A, Lupo S, Magaro HM. Oral yeast carriage in HIV-infected and non-infected populations in Rosario, Argentina. *Mycoses* 2009; 52: 53–59.
23. Sanchez-Vargas LO, Ortiz-Lopez NG, Villar M *et al.* Oral *Candida* isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico. *J Clin Microbiol* 2005; 43: 4159–4162.
24. Blignaut E, Pujol C, Joly S, Soll DR. Racial distribution of *Candida dubliniensis* colonization among South Africans. *J Clin Microbiol* 2003; 41: 1838–1842.